Sticker on chest could replace needles for kidney checks in heart failure

NCT ID NCT07349797

Recruiting now Diagnosis Sponsor: MediBeacon Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 14, 2026 · Updated 2 times

Summary

This study tests a new device that uses a sensor placed on the chest to measure kidney function in 15 adults with heart failure. Participants receive an injection of a fluorescent dye (Relmapirazin) and a standard contrast agent (iohexol), then the sensor tracks how quickly the dye clears from the skin. Researchers compare these readings to traditional blood tests to see if the sensor is accurate enough for routine use.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Relmapirazin (Lumitrace) injection and iohexol
What this could lead to: If successful, this could provide a simpler, less invasive way to monitor kidney function in heart failure patients, reducing the need for repeated blood draws.
What could go wrong: This is a very small, early study with only 15 participants, so results may not apply to everyone. The sensor's accuracy may not meet the target, and it is not a treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLOMERULAR FILTRATION RATE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLOMERULAR FILTRATION RATE HEART FAILURE

Contacts and locations

Locations

Columbia University
RECRUITING

New York, New York, 10032, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.